对比阿哌沙班和橙子：在抗磷脂综合征（APLS）治疗中使用直接口服抗凝剂（DOACs）而非华法林时需谨慎。
Comparing APLS and oranges: caution with the use of direct-acting oral anticoagulants (DOACs) instead of warfarin in the treatment of antiphospholipid syndrome (APLS).
作者信息
Benger Matthew, Vink Jasper, Snell Luke Blagdon, Breen Karen
机构信息
Guy's and Saint Thomas' NHS Foundation Trust, London, UK.
出版信息
BMJ Case Rep. 2019 Apr 1;12(4):e227695. doi: 10.1136/bcr-2018-227695.
Abstract
A 63-year-old woman with known antiphospholipid syndrome (APLS) presented with catastrophic APLS and multiorgan dysfunction after a change in her anticoagulation from warfarin to rivaroxaban. Evidence suggests direct-acting oral anticoagulants (DOACs) like rivaroxaban may be less effective than warfarin in secondary prevention of thrombotic events in high-risk APLS patients.
摘要
一名63岁患有抗磷脂综合征（APLS）的女性，在抗凝治疗从华法林转换为利伐沙班后，出现了灾难性抗磷脂综合征和多器官功能障碍。有证据表明，在高危抗磷脂综合征患者的血栓形成事件二级预防中，像利伐沙班这样的直接口服抗凝剂（DOACs）可能不如华法林有效。
相似文献
1
Comparing APLS and oranges: caution with the use of direct-acting oral anticoagulants (DOACs) instead of warfarin in the treatment of antiphospholipid syndrome (APLS).对比阿哌沙班和橙子：在抗磷脂综合征（APLS）治疗中使用直接口服抗凝剂（DOACs）而非华法林时需谨慎。
BMJ Case Rep. 2019 Apr 1;12(4):e227695. doi: 10.1136/bcr-2018-227695.
2
Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature.直接口服抗凝药物在抗磷脂综合征中的应用：这些药物是否是华法林的有效且安全的替代药物？文献系统评价。
Curr Rheumatol Rep. 2016 Dec;18(12):74. doi: 10.1007/s11926-016-0623-7.
3
Rethinking the use of direct oral anticoagulants for secondary thromboprophylaxis in patients with thrombotic antiphospholipid syndrome.重新思考在血栓性抗磷脂综合征患者中使用直接口服抗凝剂进行二级血栓预防的问题。
Drug Discov Ther. 2024 Sep 19;18(4):213-219. doi: 10.5582/ddt.2024.01050. Epub 2024 Aug 28.
4
Direct oral anticoagulants versus warfarin in patients with single antibody-positive anti-phospholipid syndrome.直接口服抗凝剂与华法林在单一抗体阳性抗磷脂综合征患者中的比较。
Eur J Haematol. 2022 Jul;109(1):69-74. doi: 10.1111/ejh.13770. Epub 2022 Apr 5.
5
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome.利伐沙班与华法林在抗磷脂抗体综合征高危患者中的比较。
Blood. 2018 Sep 27;132(13):1365-1371. doi: 10.1182/blood-2018-04-848333. Epub 2018 Jul 12.
6
The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome.56 例抗磷脂综合征患者使用直接口服抗凝剂。
Thromb Res. 2017 Apr;152:93-97. doi: 10.1016/j.thromres.2016.12.009. Epub 2016 Dec 14.
7
Direct oral anticoagulants: an alternative treatment for thrombotic antiphospholipid syndrome?直接口服抗凝剂：血栓性抗磷脂综合征的替代治疗方法？
Lupus. 2017 Oct;26(12):1297-1303. doi: 10.1177/0961203317701841. Epub 2017 Mar 29.
8
Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE.利伐沙班用于抗磷脂综合征（RAPS）的方案：一项关于利伐沙班与华法林对比治疗血栓形成性抗磷脂综合征患者（无论是否合并系统性红斑狼疮）的前瞻性、随机对照II/III期临床试验。
Lupus. 2015 Sep;24(10):1087-94. doi: 10.1177/0961203315581207. Epub 2015 May 4.
9
Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial.利伐沙班与华法林治疗血栓形成性抗磷脂综合征患者（无论是否合并系统性红斑狼疮）（RAPS）：一项随机、对照、开放标签的2/3期非劣效性试验。
Lancet Haematol. 2016 Sep;3(9):e426-36. doi: 10.1016/S2352-3026(16)30079-5.
10
Direct oral anticoagulants in antiphospholipid syndrome: a real life case series.抗磷脂综合征中直接口服抗凝剂：一个真实病例系列
Lupus. 2016 May;25(6):658-62. doi: 10.1177/0961203315624555. Epub 2016 Jan 6.
本文引用的文献
1
Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis.直接口服抗凝剂治疗的抗磷脂综合征患者血栓形成风险增加。来自国际患者水平数据荟萃分析的结果。
Autoimmun Rev. 2018 Oct;17(10):1011-1021. doi: 10.1016/j.autrev.2018.04.009. Epub 2018 Aug 11.
2
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome.利伐沙班与华法林在抗磷脂抗体综合征高危患者中的比较。
Blood. 2018 Sep 27;132(13):1365-1371. doi: 10.1182/blood-2018-04-848333. Epub 2018 Jul 12.
3
Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial.利伐沙班与华法林治疗血栓形成性抗磷脂综合征患者（无论是否合并系统性红斑狼疮）（RAPS）：一项随机、对照、开放标签的2/3期非劣效性试验。
Lancet Haematol. 2016 Sep;3(9):e426-36. doi: 10.1016/S2352-3026(16)30079-5.
4
Treatment of catastrophic antiphospholipid syndrome.灾难性抗磷脂综合征的治疗
Curr Opin Rheumatol. 2016 May;28(3):218-27. doi: 10.1097/BOR.0000000000000269.
5
Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome: Study Rationale and Design (ASTRO-APS).阿哌沙班用于抗磷脂综合征患者血栓形成的二级预防：研究原理与设计（ASTRO-APS）
Clin Appl Thromb Hemost. 2016 Apr;22(3):239-47. doi: 10.1177/1076029615615960. Epub 2015 Nov 12.
6
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.利伐沙班口服治疗有症状的肺栓塞。
N Engl J Med. 2012 Apr 5;366(14):1287-97. doi: 10.1056/NEJMoa1113572. Epub 2012 Mar 26.
7
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.利伐沙班与华法林用于非瓣膜性心房颤动。
N Engl J Med. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10.
8
Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies.抗磷脂抗体阳性患者血栓形成的预防和长期管理的循证建议：第 13 届国际抗磷脂抗体大会专题工作组报告。
Lupus. 2011 Feb;20(2):206-18. doi: 10.1177/0961203310395803.
9
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.利伐沙班与依诺肝素用于全膝关节置换术后血栓预防的比较（RECORD4）：一项随机试验。
Lancet. 2009 May 16;373(9676):1673-80. doi: 10.1016/S0140-6736(09)60734-0. Epub 2009 May 4.
10
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).关于明确抗磷脂综合征（APS）分类标准更新的国际共识声明。
J Thromb Haemost. 2006 Feb;4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753.x.
Zotero 插件